CAS9 Technology Market Research Report- Forecast To 2027

CAS9 Technology Market: Product Type (Consumables and Vectors), Application (Genome Engineering, Disease Models and In Vitro Genetic Depletion), Delivery Method (Physical Delivery Methods, Viral Delivery Methods and Non-Viral Delivery Methods) and End User (Biotechnology & Pharmaceutical Companies and Academic & Research Institutes) and Region - Global Forecast Till 2027

ID: MRFR/ICT/1532-CR | February 2019 | Region: Global | 153 pages

Please note that the assessment period of report has been updated from 2018-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Snapshot


A strong commercial interest and rising application opportunities to boost the global CAS9 technology market in the forthcoming years. The market is projected to soar at a compound annual growth rate of 11.30% between 2018 and 2023. Emergence of genome editing or gene editing with engineered nucleases has taken genetic engineering to the next level. CAS9 technology is quickly gaining prominence as a genome editing tool. Advanced countries in North America and Europe are witnessing a faster uptake of the technology. Asia Pacific is also likely to present lucrative growth opportunities to market players during the review period.


Synopsis


This MRFR report offers a detailed analysis of the global CAS9 technology market. It also includes five-year revenue analysis, ending in 2023. The report starts with a market introduction where point such as scope of study, research objective and list of assumptions are discussed. This is followed by a through discussion on market dynamics. Next, an in-depth market segment and segment analysis is furnished. This report also includes a market competitive landscape, which covers some of the top companies operating in the global CAS9 technology market.


Companies Covered


Cellecta, Inc., abm Inc., GenScript, CRISPR Therapeutic, Intellia Therapeutics, Inc., GE Healthcare, Takara Bio, Inc., AstraZeneca, PLC, Merck KGaA, Bio-Rad Laboratories, Inc., Danaher Corporation (Integrated DNA Technologies, Inc.), New England Biolabs, OriGene Technologies, Inc., Lonza Group, and Thermo Fisher Scientific.


The report offers insights into the leading market players and presents an assessment of their current market position. Company information with regards to revenue, segmental share, geographical income, SWOT, growth strategies, new product launch, M&A activities, and the latest R&D initiatives is also available in the report


Research Methodology


MRFR employs a range of scrupulously chosen methods to build a research model for drawing mission-critical insights. Use of primary methods such as personal interviews with industry decision makers allows to get an inside look. Then, the findings from primary research methods are avouched by secondary research methods such as annual reports, annual reports, SEC filings, etc. To guarantee transparency and adhere to provide reliable market data, top-down and bottom-up approaches are integrated into the research model. This allows data analysts to offer recognition of many pivotal market figures. These figures are then used to postulate weighty analysis coinciding with timely insights.


Other Description



  • Market Denomination- USD Mn

  • Base Year- 2017

  • Forecast Period- from 2018 to 2023


For the scope of the research, MRFR’s report offers a comprehensive segmental analysis of the global market for CAS9 technology


Product Type



  • Consumables

  • Vectors


Application



  • Genome engineering

  • Disease models

  • In vitro genetic depletion


Delivery Method



  • Physical delivery methods

  • Viral delivery methods

  • Non-viral delivery methods


End User



  • Biotechnology & pharmaceutical companies

  • Academic & research institutes


By Region



  • North America

  • Europe

  • Asia Pacific

  • The Middle East & Africa (MEA)

  • Latin America.


Intended Audience



  • Pharmaceutical & Biopharmaceutical companies

  • Biotechnology Companies

  • Government Research Laboratories 

  • Independent Research Laboratories

  • Market Research and Consulting Service Providers

  • Medical Research Laboratories



Frequently Asked Questions (FAQ) :


The global CAS9 technology market is expected to record a CAGR of 11.30% during the review period (2018–2023).

Growing awareness regarding biotechnology techniques and products and the increasing acceptance of gene therapy-based treatments are the major driving factors for the CAS9 technology market growth.

the associated risk factors and high prices are one of the impeding factors for the growth of the CAS9 technology market.

The North American region is expected to acquire the largest market share at 11.52% CAGR.

The physical delivery method segment of the CAS9 technology market is expanding at a 29.11% CAGR over the review period.

A few significant players of the CAS9 technology market are tech giants such as Thermo Fisher Scientific, AstraZeneca, PLC, Merck KGaA, and Bio-Rad Laboratories, Inc, among others.

The genome engineering segment is expected to record the highest growth over the assessment period.

Global CAS9 Technology Market to will witness a Double-Digit CAGR of 11.30% From 2018 to 2023. Increased focus on genome-editing is driving the popularity of the CAS9 technology. The technology allows a fast, cost-effective and accurate genetic manipulation. The prospects remain bright for CAS9 technology. Growing biotechnology sector, rising acceptance of gene therapy-based treatments, and diversified applicability of the technique are some of the major factors propelling the market forward. Given the increased awareness regarding biotechnology techniques and products, there has been a noteworthy expansion of the biotechnology sector. Investment in CAS9 is picking up steam as the application spectrum for the technology broadens further. In addition, rising acceptance of gene therapy-based treatments boosts the adoption of CAS9 technology in the medical sector. However, an undefined regulatory framework coupled with lack of awareness is undermining the market potential. Meanwhile, associated risk factors and high cost are some of the other market impediments.


Segmental Analysis


Segmental analysis of the global CAS9 technology market has been conducted on the basis of product type, application, delivery method, and end user.


Based on product type, the market has been segmented into consumables and vectors. Of these, the vectors segment accounts for the largest share of the market. In 2017, the segment stood at a market valuation of USD 1,266.8 Mn and is likely exhibit a healthy growth rate during the forecast period. Some of popular vectors include CRISPR/Cas9 vectors, Cas9 only vectors, and T7 vectors. These genome editing tools find application in drug discovery and novel therapeutics for cancer hepatitis B, HIV, among others.


Based on application, the market has been segmented into genome engineering, disease models and in vitro genetic depletion. The genome engineering segment is expected to remain highly profitable in 2019 and beyond. In 2018, the segment reached a valuation in excess of USD 800 Mn. This is primarily owing to the increase of CRISPR/Cas9 based molecular mechanism in genome engineering.


Based on delivery method, the market has been segmented into physical delivery methods, viral delivery methods and non-viral delivery methods. The physical delivery method segment holds the dominant share of the market. The segment is expected to surpass a valuation of USD 1,700 Mn by the year 2023. There is a strong preference for physical delivery method owing to its high transfection efficiency.


Based on end user, the market has been segmented into biotechnology & pharmaceutical companies and academic & research institutes.  The biotechnology & pharmaceutical companies segment accounts for the largest market share. With advances in genetic editing technology, CAS9 is drawing significant commercial interest. 


Regional Outlook 


On the basis region, the market has been segmented into Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas accounted for the largest market share in 2017 and is likely to remain high attractive throughout the assessment period. The market in Americas is expected to exhibit a CAGR of 11.52% from 2018 to 2023 and reach a valuation of over USD 1,300 Mn. Factors such as growing biotechnology industry and the faster adoption of innovative technologies in countries such the U.S. and Canada. A tremendous growth has been noticed in the biotechnology sector in the U.S. In addition, job opportunities in biotech has increased by 6.7% in 2018 as compared to 2015 in the country. Europe is the second largest market share for CAS9 technology. Rising CRISPR/CAS research activities in the pharmaceutical and biotechnology community in Europe is supporting the growth of the market.


Competition Tracking


abm Inc., Cellecta, Inc., CRISPR Therapeutic, GenScript, Danaher Corporation (Integrated DNA Technologies, Inc.), Intellia Therapeutics, Inc., New England Biolabs, GE Healthcare, OriGene Technologies, Inc. Takara Bio, Inc., Lonza Group, Thermo Fisher Scientific, AstraZeneca, PLC, Merck KGaA, and Bio-Rad Laboratories, Inc.

1 Report Prologue

2 Market Introduction

2.1 Scope of Study 18

2.2 Research Objective 18

2.3 List of Assumptions 18

3 Research Methodology

3.1 Research Process 21

3.2 Primary Research 22

3.3 Secondary Research 23

3.4 Market Size Estimation 24

4 Market Dynamics

4.1 Introduction 26

4.2 Drivers 26

4.2.1 Growing biotechnology sector followed by rising investments in the CAS9 technology supports

the market growth 26

4.2.2 Diversified applicability of the CAS9 technology enhances the potential for the market to expand 27

4.2.3 Rising acceptance of gene therapy-based treatments boosts the entry of Cas9 technology into

the medical sector 27

4.2.4 Drivers Impact Analysis 28

4.3 Restraints 28

4.3.1 Undefined regulatory framework creates a confusion in the adoption of the technology 28

4.3.2 Lack of awareness along with associated risk factors and the high cost of implementation restrain

the growth of the Cas9 technology market 28

4.3.3 Restraints Impact Analysis 29

4.4 Opportunity 29

4.4.1 Growing biotechnology sector in developing economies such as India 29

5 Market Factor Analysis

5.1 Value Chain Analysis 31

5.1.1 R&D and Designing 31

5.1.2 Manufacturing 31

5.1.3 Distribution & Sales 32

5.1.4 Post-Sales Review 32


5.2 Porter’s Five Forces Model 33

5.2.1 Threat of New Entrants 33

5.2.2 Bargaining Power of Suppliers 33

5.2.3 Threat of Substitutes 34

5.2.4 Bargaining Power of Buyers 34

5.2.5 Intensity of Rivalry 34

5.3 Industry Trends 35

5.3.1 The CAS9 technology is revolutionizing genome engineering 35

5.3.2 Funding Scenario 35

6 Global CAS9 Technology Market, by Product Type

6.1 Introduction 37

6.2 Consumables 38

6.3 Vectors 38

7 Global CAS9 Technology Market, by Application

7.1 Introduction 40

7.2 Genome engineering 41

7.3 Disease Models 41

7.4 In vitro genetic depletion 42

8 Global CAS9 Technology Market, by Delivery Method

8.1 Introduction 44

8.2 Physical Delivery Methods 45

8.3 Viral Delivery Methods 45

8.4 Non-Viral Delivery Methods 45

9 Global CAS9 Technology Market, by End User

9.1 Introduction 47

9.2 Biotechnology & Pharmaceutical Companies 48

9.3 Academic & Research Institutes 48

10 Global CAS9 Technology Market, by Regions

10.1 Introduction 50

10.2 Americas 51

10.2.1 North America 54

10.2.1.1 U.S 56

10.2.1.2 Canada 59

10.2.2 South America 61


10.3 Europe 64

10.3.1 Western Europe 67

10.3.1.1 Germany 70

10.3.1.2 U.K 72

10.3.1.3 France 75

10.3.1.4 Italy 77

10.3.1.5 Spain 80

10.3.1.6 Rest of Western Europe 82

10.3.2 Eastern Europe 85

10.4 Asia Pacific 88

10.4.1 Japan 91

10.4.2 China 93

10.4.3 India 96

10.4.4 Australia 98

10.4.5 South Korea 101

10.4.6 Rest of Asia Pacific 103

10.5 Middle East & Africa 106

10.5.1 Middle East 109

10.5.2 Africa 111

11 Competitive Landscape

11.1 Introduction 115

12 Company Profiles

12.1 abm Inc. 117

12.1.1 Financial Overview 117

12.1.2 Products Offering 117

12.1.3 Key Developments 117

12.1.4 SWOT Analysis 118

12.1.5 Key Strategy 118

12.2 Cellecta, Inc. 119

12.2.1 Company Overview 119

12.2.2 Financial Overview 119

12.2.3 Products Offering 119

12.2.4 Key Developments 120

12.2.5 SWOT Analysis 120

12.2.6 Key Strategy 120

12.3 CRISPR Therapeutics 121

12.3.1 Company Overview 121

12.3.2 Financial Overview 121

12.3.3 Key Developments 121

12.3.4 SWOT Analysis 122

12.3.5 Key Strategy 122

12.4 GenScript 123

12.4.1 Company Overview 123

12.4.2 Financial Overview 123

12.4.3 Products Offering 124

12.4.4 Key Developments 124

12.4.5 SWOT Analysis 125

12.4.6 Key Strategy 125

12.5 Danaher Corporation (Integrated DNA Technologies, Inc.) 126

12.5.1 Company Overview 126

12.5.2 Financial Overview 126

12.5.3 Products Offering 127

12.5.4 Key Developments 127

12.5.5 SWOT Analysis 128

12.5.6 Key Strategy 128

12.6 Intellia Therapeutics, Inc. 129

12.6.1 Company Overview 129

12.6.2 Financial Overview 129

12.6.3 Pipeline Products 129

12.6.4 Key Developments 130

12.6.5 SWOT Analysis 130

12.6.6 Key Strategy 130

12.7 New England Biolabs 131

12.7.1 Company Overview 131

12.7.2 Financial Overview: 131

12.7.3 Products Offering 131

12.7.4 Key Developments 131

12.7.5 SWOT Analysis 132

12.7.6 Key Strategy 132

12.8 GE Healthcare 133

12.8.1 Company Overview 133

12.8.2 Financial Overview 133

12.8.3 Products Offering 134

12.8.4 Key Developments 134

12.8.5 SWOT Analysis 134

12.8.6 Key Strategy 134

12.9 OriGene Technologies, Inc. 135

12.9.1 Company Overview 135

12.9.2 Financial Overview 135

12.9.3 Products Offering 135

12.9.4 Key Developments 135

12.9.5 SWOT Analysis 136

12.9.6 Key Strategy 136

12.10 Takara Bio, Inc. 137

12.10.1 Company Overview 137

12.10.2 Financial Overview 137

12.10.3 Products Offering 138

12.10.4 Key Developments 138

12.10.5 SWOT Analysis 138

12.10.6 Key Strategy 138

12.11 Lonza Group 139

12.11.1 Company Overview 139

12.11.2 Financial Overview 139

12.11.3 Products Offering 140

12.11.4 Key Developments 140

12.11.5 SWOT Analysis 140

12.11.6 Key Strategy 140

12.12 Thermo Fisher Scientific 141

12.12.1 Company Overview 141

12.12.2 Financial Overview 141

12.12.3 Products Offering 142

12.12.4 Key Developments 142

12.12.5 SWOT Analysis 142

12.12.6 Key Strategy 143

12.13 AstraZeneca, PLC 144

12.13.1 Company Overview 144

12.13.2 Financial Overview 144

12.13.3 Products Offering 145

12.13.4 Key Developments 145

12.13.5 SWOT Analysis 145

12.13.6 Key Strategy 145

12.14 Merck KGaA 146

12.14.1 Company Overview 146

12.14.2 Financial Overview 146

12.14.3 Products Offering 147

12.14.4 Key Developments 147

12.14.5 SWOT Analysis 147

12.14.6 Key Strategy 147

12.15 Bio-Rad Laboratories, Inc. 148

12.15.1 Company Overview 148

12.15.2 Financial Overview 148

12.15.3 Products Offering 149

12.15.4 Key Developments 149

12.15.5 SWOT Analysis 149

12.15.6 Key Strategy 149

13 Appendix

13.1 Discussion Blue Print 151

14 List of Tables

TABLE 1 LIST OF ASSUMPTIONS 18

TABLE 2 PRIMARY INTERVIEWS 21

TABLE 3 GLOBAL CAS9 TECHNOLOGY MARKET BY PRODUCT TYPE 2020-2027 (USD MILLION) 37

TABLE 4 GLOBAL CAS9 TECHNOLOGY MARKET FOR CONSUMABLES 2020-2027 (USD MILLION) 38

TABLE 5 GLOBAL CAS9 TECHNOLOGY MARKET FOR VECTORS 2020-2027 (USD MILLION) 38

TABLE 6 GLOBAL CAS9 TECHNOLOGY MARKET BY APPLICATION 2020-2027 (USD MILLION) 40

TABLE 7 GLOBAL CAS9 TECHNOLOGY MARKET FOR GENOME ENGINEERING 2020-2027 (USD MILLION) 41

TABLE 8 GLOBAL CAS9 TECHNOLOGY MARKET FOR DISEASE MODELS 2020-2027 (USD MILLION) 41

TABLE 9 GLOBAL CAS9 TECHNOLOGY MARKET FOR IN VITRO GENETIC DEPLETION 2020-2027 (USD MILLION) 42

TABLE 10 GLOBAL CAS9 TECHNOLOGY MARKET BY DELIVERY METHOD 2020-2027 (USD MILLION) 44

TABLE 11 GLOBAL CAS9 TECHNOLOGY MARKET FOR PHYSICAL DELIVERY METHODS 2020-2027 (USD MILLION) 45

TABLE 12 GLOBAL CAS9 TECHNOLOGY MARKET FOR VIRAL DELIVERY METHODS 2020-2027 (USD MILLION) 45

TABLE 13 GLOBAL CAS9 TECHNOLOGY MARKET FOR NON-VIRAL DELIVERY METHODS 2020-2027 (USD MILLION) 45

TABLE 14 GLOBAL CAS9 TECHNOLOGY MARKET BY END USER 2020-2027 (USD MILLION) 47

TABLE 15 GLOBAL CAS9 TECHNOLOGY MARKET FOR BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES 2020-2027 (USD MILLION) 48

TABLE 16 GLOBAL CAS9 TECHNOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES 2020-2027 (USD MILLION) 48

TABLE 17 GLOBAL CAS9 TECHNOLOGY MARKET BY REGIONS 2020-2027 (USD MILLION) 50

TABLE 18 AMERICAS CAS9 TECHNOLOGY MARKET BY REGIONS 2020-2027 (USD MILLION) 51

TABLE 19 AMERICAS CAS9 TECHNOLOGY MARKET BY PRODUCT TYPE 2020-2027 (USD MILLION) 52

TABLE 20 AMERICAS CAS9 TECHNOLOGY MARKET BY APPLICATION 2020-2027 (USD MILLION) 52

TABLE 21 AMERICAS CAS9 TECHNOLOGY MARKET BY DELIVERY METHOD 2020-2027 (USD MILLION) 52

TABLE 22 AMERICAS CAS9 TECHNOLOGY MARKET BY PHYSICAL DELIVERY METHODS 2020-2027 (USD MILLION) 52

TABLE 23 AMERICAS CAS9 TECHNOLOGY MARKET BY VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 53

TABLE 24 AMERICAS CAS9 TECHNOLOGY MARKET BY NON-VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 53

TABLE 25 AMERICAS CAS9 TECHNOLOGY MARKET BY END USER 2020-2027 (USD MILLION) 53

TABLE 26 AMERICAS CAS9 TECHNOLOGY MARKET BY COUNTRY 2020-2027 (USD MILLION) 54

TABLE 27 NORTH AMERICA CAS9 TECHNOLOGY MARKET BY PRODUCT TYPE 2020-2027 (USD MILLION) 54

TABLE 28 NORTH AMERICA CAS9 TECHNOLOGY MARKET BY APPLICATION 2020-2027 (USD MILLION) 54

TABLE 29 NORTH AMERICA CAS9 TECHNOLOGY MARKET BY DELIVERY METHOD 2020-2027 (USD MILLION) 54

TABLE 30 NORTH AMERICA CAS9 TECHNOLOGY MARKET BY PHYSICAL DELIVERY METHODS 2020-2027 (USD MILLION) 55

TABLE 31 NORTH AMERICA CAS9 TECHNOLOGY MARKET BY VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 55

TABLE 32 NORTH AMERICA CAS9 TECHNOLOGY MARKET BY NON-VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 55

TABLE 33 NORTH AMERICA CAS9 TECHNOLOGY MARKET BY END USER 2020-2027 (USD MILLION) 56

TABLE 34 U.S CAS9 TECHNOLOGY MARKET BY PRODUCT TYPE 2020-2027 (USD MILLION) 56

TABLE 35 U.S CAS9 TECHNOLOGY MARKET BY APPLICATION 2020-2027 (USD MILLION) 56

TABLE 36 U.S CAS9 TECHNOLOGY MARKET BY DELIVERY METHOD 2020-2027 (USD MILLION) 57

TABLE 37 U.S CAS9 TECHNOLOGY MARKET BY PHYSICAL DELIVERY METHODS 2020-2027 (USD MILLION) 57

TABLE 38 U.S CAS9 TECHNOLOGY MARKET BY VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 57

TABLE 39 U.S CAS9 TECHNOLOGY MARKET BY NON-VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 58

TABLE 40 U.S CAS9 TECHNOLOGY MARKET BY END USER 2020-2027 (USD MILLION) 58

TABLE 41 CANADA CAS9 TECHNOLOGY MARKET BY PRODUCT TYPE 2020-2027 (USD MILLION) 59

TABLE 42 CANADA CAS9 TECHNOLOGY MARKET BY APPLICATION 2020-2027 (USD MILLION) 59

TABLE 43 CANADA CAS9 TECHNOLOGY MARKET BY DELIVERY METHOD 2020-2027 (USD MILLION) 59

TABLE 44 CANADA CAS9 TECHNOLOGY MARKET BY PHYSICAL DELIVERY METHODS 2020-2027 (USD MILLION) 60

TABLE 45 CANADA CAS9 TECHNOLOGY MARKET BY VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 60

TABLE 46 CANADA CAS9 TECHNOLOGY MARKET BY NON-VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 60

TABLE 47 CANADA CAS9 TECHNOLOGY MARKET BY END USER 2020-2027 (USD MILLION) 61

TABLE 48 SOUTH AMERICA CAS9 TECHNOLOGY MARKET BY PRODUCT TYPE 2020-2027 (USD MILLION) 61

TABLE 49 SOUTH AMERICA CAS9 TECHNOLOGY MARKET BY APPLICATION 2020-2027 (USD MILLION) 61

TABLE 50 SOUTH AMERICA CAS9 TECHNOLOGY MARKET BY DELIVERY METHOD 2020-2027 (USD MILLION) 62

TABLE 51 SOUTH AMERICA CAS9 TECHNOLOGY MARKET BY PHYSICAL DELIVERY METHODS 2020-2027 (USD MILLION) 62

TABLE 52 SOUTH AMERICA CAS9 TECHNOLOGY MARKET BY VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 62

TABLE 53 SOUTH AMERICA CAS9 TECHNOLOGY MARKET BY NON-VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 63

TABLE 54 SOUTH AMERICA CAS9 TECHNOLOGY MARKET BY END USER 2020-2027 (USD MILLION) 63

TABLE 55 EUROPE CAS9 TECHNOLOGY MARKET BY REGIONS 2020-2027 (USD MILLION) 64

TABLE 56 EUROPE CAS9 TECHNOLOGY MARKET BY PRODUCT TYPE 2020-2027 (USD MILLION) 64

TABLE 57 EUROPE CAS9 TECHNOLOGY MARKET BY APPLICATION 2020-2027 (USD MILLION) 65

TABLE 58 EUROPE CAS9 TECHNOLOGY MARKET BY DELIVERY METHOD 2020-2027 (USD MILLION) 65

TABLE 59 EUROPE CAS9 TECHNOLOGY MARKET BY PHYSICAL DELIVERY METHODS 2020-2027 (USD MILLION) 65

TABLE 60 EUROPE CAS9 TECHNOLOGY MARKET BY VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 66

TABLE 61 EUROPE CAS9 TECHNOLOGY MARKET BY NON-VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 66

TABLE 62 EUROPE CAS9 TECHNOLOGY MARKET BY END USER 2020-2027 (USD MILLION) 66

TABLE 63 WESTERN EUROPE CAS9 TECHNOLOGY MARKET BY COUNTRY 2020-2027 (USD MILLION) 67

TABLE 64 WESTERN EUROPE CAS9 TECHNOLOGY MARKET BY PRODUCT TYPE 2020-2027 (USD MILLION) 67

TABLE 65 WESTERN EUROPE CAS9 TECHNOLOGY MARKET BY APPLICATION 2020-2027 (USD MILLION) 67

TABLE 66 WESTERN EUROPE CAS9 TECHNOLOGY MARKET BY DELIVERY METHOD 2020-2027 (USD MILLION) 68

TABLE 67 WESTERN EUROPE CAS9 TECHNOLOGY MARKET BY PHYSICAL DELIVERY METHODS 2020-2027 (USD MILLION) 68

TABLE 68 WESTERN EUROPE CAS9 TECHNOLOGY MARKET BY VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 68

TABLE 69 WESTERN EUROPE CAS9 TECHNOLOGY MARKET BY NON-VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 69

TABLE 70 WESTERN EUROPE CAS9 TECHNOLOGY MARKET BY END USER 2020-2027 (USD MILLION) 69

TABLE 71 GERMANY CAS9 TECHNOLOGY MARKET BY PRODUCT TYPE 2020-2027 (USD MILLION) 70

TABLE 72 GERMANY CAS9 TECHNOLOGY MARKET BY APPLICATION 2020-2027 (USD MILLION) 70

TABLE 73 GERMANY CAS9 TECHNOLOGY MARKET BY DELIVERY METHOD 2020-2027 (USD MILLION) 70

TABLE 74 GERMANY CAS9 TECHNOLOGY MARKET BY PHYSICAL DELIVERY METHODS 2020-2027 (USD MILLION) 71

TABLE 75 GERMANY CAS9 TECHNOLOGY MARKET BY VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 71

TABLE 76 GERMANY CAS9 TECHNOLOGY MARKET BY NON-VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 71

TABLE 77 GERMANY CAS9 TECHNOLOGY MARKET BY END USER 2020-2027 (USD MILLION) 72

TABLE 78 U.K CAS9 TECHNOLOGY MARKET BY PRODUCT TYPE 2020-2027 (USD MILLION) 72

TABLE 79 U.K CAS9 TECHNOLOGY MARKET BY APPLICATION 2020-2027 (USD MILLION) 72

TABLE 80 U.K CAS9 TECHNOLOGY MARKET BY DELIVERY METHOD 2020-2027 (USD MILLION) 73

TABLE 81 U.K CAS9 TECHNOLOGY MARKET BY PHYSICAL DELIVERY METHODS 2020-2027 (USD MILLION) 73

TABLE 82 U.K CAS9 TECHNOLOGY MARKET BY VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 73

TABLE 83 U.K CAS9 TECHNOLOGY MARKET BY NON-VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 74

TABLE 84 U.K CAS9 TECHNOLOGY MARKET BY END USER 2020-2027 (USD MILLION) 74

TABLE 85 FRANCE CAS9 TECHNOLOGY MARKET BY PRODUCT TYPE 2020-2027 (USD MILLION) 75

TABLE 86 FRANCE CAS9 TECHNOLOGY MARKET BY APPLICATION 2020-2027 (USD MILLION) 75

TABLE 87 FRANCE CAS9 TECHNOLOGY MARKET BY DELIVERY METHOD 2020-2027 (USD MILLION) 75

TABLE 88 FRANCE CAS9 TECHNOLOGY MARKET BY PHYSICAL DELIVERY METHODS 2020-2027 (USD MILLION) 76

TABLE 89 FRANCE CAS9 TECHNOLOGY MARKET BY VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 76

TABLE 90 FRANCE CAS9 TECHNOLOGY MARKET BY NON-VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 76

TABLE 91 FRANCE CAS9 TECHNOLOGY MARKET BY END USER 2020-2027 (USD MILLION) 77

TABLE 92 ITALY CAS9 TECHNOLOGY MARKET BY PRODUCT TYPE 2020-2027 (USD MILLION) 77

TABLE 93 ITALY CAS9 TECHNOLOGY MARKET BY APPLICATION 2020-2027 (USD MILLION) 77

TABLE 94 ITALY CAS9 TECHNOLOGY MARKET BY DELIVERY METHOD 2020-2027 (USD MILLION) 78

TABLE 95 ITALY CAS9 TECHNOLOGY MARKET BY PHYSICAL DELIVERY METHODS 2020-2027 (USD MILLION) 78

TABLE 96 ITALY CAS9 TECHNOLOGY MARKET BY VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 78

TABLE 97 ITALY CAS9 TECHNOLOGY MARKET BY NON-VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 79

TABLE 98 ITALY CAS9 TECHNOLOGY MARKET BY END USER 2020-2027 (USD MILLION) 79

TABLE 99 SPAIN CAS9 TECHNOLOGY MARKET BY PRODUCT TYPE 2020-2027 (USD MILLION) 80

TABLE 100 SPAIN CAS9 TECHNOLOGY MARKET BY APPLICATION 2020-2027 (USD MILLION) 80

TABLE 101 SPAIN CAS9 TECHNOLOGY MARKET BY DELIVERY METHOD 2020-2027 (USD MILLION) 80

TABLE 102 SPAIN CAS9 TECHNOLOGY MARKET BY PHYSICAL DELIVERY METHODS 2020-2027 (USD MILLION) 81

TABLE 103 SPAIN CAS9 TECHNOLOGY MARKET BY VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 81

TABLE 104 SPAIN CAS9 TECHNOLOGY MARKET BY NON-VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 81

TABLE 105 SPAIN CAS9 TECHNOLOGY MARKET BY END USER 2020-2027 (USD MILLION) 82

TABLE 106 REST OF WESTERN EUROPE CAS9 TECHNOLOGY MARKET BY PRODUCT TYPE 2020-2027 (USD MILLION) 82

TABLE 107 REST OF WESTERN EUROPE CAS9 TECHNOLOGY MARKET BY APPLICATION 2020-2027 (USD MILLION) 82

TABLE 108 REST OF WESTERN EUROPE CAS9 TECHNOLOGY MARKET BY DELIVERY METHOD 2020-2027 (USD MILLION) 83

TABLE 109 REST OF WESTERN EUROPE CAS9 TECHNOLOGY MARKET BY PHYSICAL DELIVERY METHODS 2020-2027 (USD MILLION) 83

TABLE 110 REST OF WESTERN EUROPE CAS9 TECHNOLOGY MARKET BY VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 83

TABLE 111 REST OF WESTERN EUROPE CAS9 TECHNOLOGY MARKET BY NON-VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 84

TABLE 112 REST OF WESTERN EUROPE CAS9 TECHNOLOGY MARKET BY END USER 2020-2027 (USD MILLION) 84

TABLE 113 EASTERN EUROPE CAS9 TECHNOLOGY MARKET BY PRODUCT TYPE 2020-2027 (USD MILLION) 85

TABLE 114 EASTERN EUROPE CAS9 TECHNOLOGY MARKET BY APPLICATION 2020-2027 (USD MILLION) 85

TABLE 115 EASTERN EUROPE CAS9 TECHNOLOGY MARKET BY DELIVERY METHOD 2020-2027 (USD MILLION) 85

TABLE 116 EASTERN EUROPE CAS9 TECHNOLOGY MARKET BY PHYSICAL DELIVERY METHODS 2020-2027 (USD MILLION) 86

TABLE 117 EASTERN EUROPE CAS9 TECHNOLOGY MARKET BY VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 86

TABLE 118 EASTERN EUROPE CAS9 TECHNOLOGY MARKET BY NON-VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 86

TABLE 119 EASTERN EUROPE CAS9 TECHNOLOGY MARKET BY END USER 2020-2027 (USD MILLION) 87

TABLE 120 ASIA PACIFIC CAS9 TECHNOLOGY MARKET BY REGIONS 2020-2027 (USD MILLION) 88

TABLE 121 ASIA PACIFIC CAS9 TECHNOLOGY MARKET BY PRODUCT TYPE 2020-2027 (USD MILLION) 88

TABLE 122 ASIA PACIFIC CAS9 TECHNOLOGY MARKET BY APPLICATION 2020-2027 (USD MILLION) 89

TABLE 123 ASIA PACIFIC CAS9 TECHNOLOGY MARKET BY DELIVERY METHOD 2020-2027 (USD MILLION) 89

TABLE 124 ASIA PACIFIC CAS9 TECHNOLOGY MARKET BY PHYSICAL DELIVERY METHODS 2020-2027 (USD MILLION) 89

TABLE 125 ASIA PACIFIC CAS9 TECHNOLOGY MARKET BY VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 90

TABLE 126 ASIA PACIFIC CAS9 TECHNOLOGY MARKET BY NON-VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 90

TABLE 127 ASIA PACIFIC CAS9 TECHNOLOGY MARKET BY END USER 2020-2027 (USD MILLION) 90

TABLE 128 JAPAN CAS9 TECHNOLOGY MARKET BY PRODUCT TYPE 2020-2027 (USD MILLION) 91

TABLE 129 JAPAN CAS9 TECHNOLOGY MARKET BY APPLICATION 2020-2027 (USD MILLION) 91

TABLE 130 JAPAN CAS9 TECHNOLOGY MARKET BY DELIVERY METHOD 2020-2027 (USD MILLION) 91

TABLE 131 JAPAN CAS9 TECHNOLOGY MARKET BY PHYSICAL DELIVERY METHODS 2020-2027 (USD MILLION) 92

TABLE 132 JAPAN CAS9 TECHNOLOGY MARKET BY VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 92

TABLE 133 JAPAN CAS9 TECHNOLOGY MARKET BY NON-VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 92

TABLE 134 JAPAN CAS9 TECHNOLOGY MARKET BY END USER 2020-2027 (USD MILLION) 93

TABLE 135 CHINA CAS9 TECHNOLOGY MARKET BY PRODUCT TYPE 2020-2027 (USD MILLION) 93

TABLE 136 CHINA CAS9 TECHNOLOGY MARKET BY APPLICATION 2020-2027 (USD MILLION) 93

TABLE 137 CHINA CAS9 TECHNOLOGY MARKET BY DELIVERY METHOD 2020-2027 (USD MILLION) 94

TABLE 138 CHINA CAS9 TECHNOLOGY MARKET BY PHYSICAL DELIVERY METHODS 2020-2027 (USD MILLION) 94

TABLE 139 CHINA CAS9 TECHNOLOGY MARKET BY VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 94

TABLE 140 CHINA CAS9 TECHNOLOGY MARKET BY NON-VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 95

TABLE 141 CHINA CAS9 TECHNOLOGY MARKET BY END USER 2020-2027 (USD MILLION) 95

TABLE 142 INDIA CAS9 TECHNOLOGY MARKET BY PRODUCT TYPE 2020-2027 (USD MILLION) 96

TABLE 143 INDIA CAS9 TECHNOLOGY MARKET BY APPLICATION 2020-2027 (USD MILLION) 96

TABLE 144 INDIA CAS9 TECHNOLOGY MARKET BY DELIVERY METHOD 2020-2027 (USD MILLION) 96

TABLE 145 INDIA CAS9 TECHNOLOGY MARKET BY PHYSICAL DELIVERY METHODS 2020-2027 (USD MILLION) 97

TABLE 146 INDIA CAS9 TECHNOLOGY MARKET BY VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 97

TABLE 147 INDIA CAS9 TECHNOLOGY MARKET BY NON-VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 97

TABLE 148 INDIA CAS9 TECHNOLOGY MARKET BY END USER 2020-2027 (USD MILLION) 98

TABLE 149 AUSTRALIA CAS9 TECHNOLOGY MARKET BY PRODUCT TYPE 2020-2027 (USD MILLION) 98

TABLE 150 AUSTRALIA CAS9 TECHNOLOGY MARKET BY APPLICATION 2020-2027 (USD MILLION) 98

TABLE 151 AUSTRALIA CAS9 TECHNOLOGY MARKET BY DELIVERY METHOD 2020-2027 (USD MILLION) 99

TABLE 152 AUSTRALIA CAS9 TECHNOLOGY MARKET BY PHYSICAL DELIVERY METHODS 2020-2027 (USD MILLION) 99

TABLE 153 AUSTRALIA CAS9 TECHNOLOGY MARKET BY VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 99

TABLE 154 AUSTRALIA CAS9 TECHNOLOGY MARKET BY NON-VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 100

TABLE 155 AUSTRALIA CAS9 TECHNOLOGY MARKET BY END USER 2020-2027 (USD MILLION) 100

TABLE 156 SOUTH KOREA CAS9 TECHNOLOGY MARKET BY PRODUCT TYPE 2020-2027 (USD MILLION) 101

TABLE 157 SOUTH KOREA CAS9 TECHNOLOGY MARKET BY APPLICATION 2020-2027 (USD MILLION) 101

TABLE 158 SOUTH KOREA CAS9 TECHNOLOGY MARKET BY DELIVERY METHOD 2020-2027 (USD MILLION) 101

TABLE 159 SOUTH KOREA CAS9 TECHNOLOGY MARKET BY PHYSICAL DELIVERY METHODS 2020-2027 (USD MILLION) 102

TABLE 160 SOUTH KOREA CAS9 TECHNOLOGY MARKET BY VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 102

TABLE 161 SOUTH KOREA CAS9 TECHNOLOGY MARKET BY NON-VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 102

TABLE 162 SOUTH KOREA CAS9 TECHNOLOGY MARKET BY END USER 2020-2027 (USD MILLION) 103

TABLE 163 REST OF ASIA PACIFIC CAS9 TECHNOLOGY MARKET BY PRODUCT TYPE 2020-2027 (USD MILLION) 103

TABLE 164 REST OF ASIA PACIFIC CAS9 TECHNOLOGY MARKET BY APPLICATION 2020-2027 (USD MILLION) 103

TABLE 165 REST OF ASIA PACIFIC CAS9 TECHNOLOGY MARKET BY DELIVERY METHOD 2020-2027 (USD MILLION) 104

TABLE 166 REST OF ASIA PACIFIC CAS9 TECHNOLOGY MARKET BY PHYSICAL DELIVERY METHODS 2020-2027 (USD MILLION) 104

TABLE 167 REST OF ASIA PACIFIC CAS9 TECHNOLOGY MARKET BY VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 104

TABLE 168 REST OF ASIA PACIFIC CAS9 TECHNOLOGY MARKET BY NON-VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 105

TABLE 169 REST OF ASIA PACIFIC CAS9 TECHNOLOGY MARKET BY END USER 2020-2027 (USD MILLION) 105

TABLE 170 MIDDLE EAST & AFRICA CAS9 TECHNOLOGY MARKET BY REGIONS 2020-2027 (USD MILLION) 106

TABLE 171 MIDDLE EAST & AFRICA CAS9 TECHNOLOGY MARKET BY PRODUCT TYPE 2020-2027 (USD MILLION) 106

TABLE 172 MIDDLE EAST & AFRICA CAS9 TECHNOLOGY MARKET BY APPLICATION 2020-2027 (USD MILLION) 107

TABLE 173 MIDDLE EAST & AFRICA CAS9 TECHNOLOGY MARKET BY DELIVERY METHOD 2020-2027 (USD MILLION) 107

TABLE 174 MIDDLE EAST & AFRICA CAS9 TECHNOLOGY MARKET BY PHYSICAL DELIVERY METHODS 2020-2027 (USD MILLION) 107

TABLE 175 MIDDLE EAST & AFRICA CAS9 TECHNOLOGY MARKET BY VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 108

TABLE 176 MIDDLE EAST & AFRICA CAS9 TECHNOLOGY MARKET BY NON-VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 108

TABLE 177 MIDDLE EAST & AFRICA CAS9 TECHNOLOGY MARKET BY END USER 2020-2027 (USD MILLION) 108

TABLE 178 MIDDLE EAST CAS9 TECHNOLOGY MARKET BY PRODUCT TYPE 2020-2027 (USD MILLION) 109

TABLE 179 MIDDLE EAST CAS9 TECHNOLOGY MARKET BY APPLICATION 2020-2027 (USD MILLION) 109

TABLE 180 MIDDLE EAST CAS9 TECHNOLOGY MARKET BY DELIVERY METHOD 2020-2027 (USD MILLION) 109

TABLE 181 MIDDLE EAST CAS9 TECHNOLOGY MARKET BY PHYSICAL DELIVERY METHODS 2020-2027 (USD MILLION) 110

TABLE 182 MIDDLE EAST CAS9 TECHNOLOGY MARKET BY VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 110

TABLE 183 MIDDLE EAST CAS9 TECHNOLOGY MARKET BY NON-VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 110

TABLE 184 MIDDLE EAST CAS9 TECHNOLOGY MARKET BY END USER 2020-2027 (USD MILLION) 111

TABLE 185 AFRICA CAS9 TECHNOLOGY MARKET BY PRODUCT TYPE 2020-2027 (USD MILLION) 111

TABLE 186 AFRICA CAS9 TECHNOLOGY MARKET BY APPLICATION 2020-2027 (USD MILLION) 111

TABLE 187 AFRICA CAS9 TECHNOLOGY MARKET BY DELIVERY METHOD 2020-2027 (USD MILLION) 112

TABLE 188 AFRICA CAS9 TECHNOLOGY MARKET BY PHYSICAL DELIVERY METHODS 2020-2027 (USD MILLION) 112

TABLE 189 AFRICA CAS9 TECHNOLOGY MARKET BY VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 112

TABLE 190 AFRICA CAS9 TECHNOLOGY MARKET BY NON-VIRAL DELIVERY METHOD 2020-2027 (USD MILLION) 113

TABLE 191 AFRICA CAS9 TECHNOLOGY MARKET BY END USER 2020-2027 (USD MILLION) 113

TABLE 192 MAJOR PLAYERS IN THE GLOBAL CAS9 TECHNOLOGY MARKET 115


15 List of Figures

FIGURE 1 GLOBAL CAS9 TECHNOLOGY MARKET: MARKET STRUCTURE 19

FIGURE 2 RESEARCH PROCESS 21

FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH 24

FIGURE 4 MARKET DYNAMICS ANALYSIS OF THE GLOBAL CAS9 TECHNOLOGY MARKET 26

FIGURE 5 DRIVERS IMPACT ANALYSIS: GLOBAL CAS9 TECHNOLOGY MARKET 28

FIGURE 6 RESTRAINTS IMPACT ANALYSIS: GLOBAL CAS9 TECHNOLOGY MARKET 29

FIGURE 7 VALUE CHAIN: GLOBAL CAS9 TECHNOLOGY MARKET 31

FIGURE 8 PORTER’S FIVE FORCES MODEL: GLOBAL CAS9 TECHNOLOGY MARKET 33

FIGURE 9 GLOBAL CAS9 TECHNOLOGY MARKET BY PRODUCT TYPE 2020&2027 (USD MILLION) 37

FIGURE 10 GLOBAL CAS9 TECHNOLOGY MARKET BY APPLICATION 2020&2027 (USD MILLION) 41

FIGURE 11 GLOBAL CAS9 TECHNOLOGY MARKET BY DELIVERY METHOD 2020&2027 (USD MILLION) 44

FIGURE 12 GLOBAL CAS9 TECHNOLOGY MARKET BY END USER 2020&2027 (USD MILLION) 47

FIGURE 13 GLOBAL CAS9 TECHNOLOGY MARKET SHARE BY REGIONS 2020 (%) 51

FIGURE 14 AMERICAS CAS9 TECHNOLOGY MARKET SHARE BY REGIONS 2020 (%) 51

FIGURE 15 EUROPE CAS9 TECHNOLOGY MARKET SHARE BY REGIONS 2020 (%) 64

FIGURE 16 ASIA PACIFIC CAS9 TECHNOLOGY MARKET SHARE BY REGIONS 2020 (%) 88

FIGURE 17 MIDDLE EAST & AFRICA CAS9 TECHNOLOGY MARKET SHARE BY REGIONS 2020 (%) 106

Global CAS9 technology market: Competitive Landscape


A number of industries are using CAS9 technology for the development and production of new drugs for various diseases. Through extensive research, it is found out that the market players have adopted different strategies to develop better and cost-effective products, also under gone mergers and acquisition. Some key players operating in this market: Intellia Therapeutics, Inc, Novartis AG, Bayer AG, and CRISPR THERAPEUTICS.  Many leading players are concentrated in the Americas owing to well-established market and high healthcare expenditures; these players have expanded their market in other region as well.


Intellia Therapeutics, Inc a gene-editing company and develops novel therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. It is involved in developing treatments with the potential to cure serious diseases such as cancer, autoimmune diseases, liver diseases, and others. The company is also involved in mergers and acquisitions. In April 2016 Intellia Therapeutics, Inc   collaborated with Regeneron Pharmaceuticals, Inc. to advance the CRISPR/Cas gene-editing technology for in vivo therapeutic development.


CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. Its leading product targets blood diseases β-thalassemia and sickle cell disease using the ex vivo approach. The key strategies adopted by the company are mergers, acquisition and strategic collaborations to increase their business. In August 2017, the company announced its collaboration with Massachusetts General Hospital to Research Use of CRISPR/Cas9 in T Cell Cancer Therapies, thus enabling the development of next generation of T cell therapies in oncology.


Bayer AG is a German pharmaceutical and life sciences company. It operates in a wide range of areas of business including human and veterinary pharmaceuticals, consumer healthcare products, agricultural chemicals and biotechnology products, and high-value polymers. The pharmaceuticals division of the company focuses on prescription products in the areas of cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology, and ophthalmology. In August 2016, Bayer AG and CRISPR Therapeutics started a joint venture, named Casebia Therapeutics, in Cambridge to develop, discover and commercialize new therapeutics to cure blood blindness, disorders, and congenital heart disease.


Each of them is committed to providing high-quality products to enhance patient care. These players established themselves as major companies across the globe. They are investing in research, awareness, marketing and technology advancement. The also focus on acquisitions, collaborations, partnerships, expansion and new product launches to obtain maximum market share.